What Is AOD-9604?
AOD-9604 (Advanced Obesity Drug 9604) is a synthetic peptide fragment derived from the C-terminal (tail-end) region of the human growth hormone (hGH) molecule. Specifically, it corresponds to amino acid positions 176–191 of the hGH sequence, with a critical modification: an additional tyrosine residue added to the N-terminus (the starting end of the peptide chain) to enhance stability.
You may also see it referenced under the name HGH Fragment 176-191, which refers to the same region without the tyrosine addition — a closely related compound that researchers often study in parallel. The two share substantial structural and functional overlap, though AOD-9604's modification is intended to improve molecular stability in research settings.
The rationale for isolating this particular fragment was elegant: researchers hypothesized that the fat-metabolizing properties attributed to growth hormone might reside in a specific segment of the molecule, separate from the growth-promoting effects. If that hypothesis held, a fragment could potentially be studied for its lipolytic (fat-breakdown) properties without the mitogenic (cell-growth-stimulating) activity of full-length hGH.
Research suggests that AOD-9604 retains the lipolytic (fat-mobilizing) activity** of full-length growth hormone without stimulating the IGF-1 axis — the pathway associated with tissue growth and proliferation.
Mechanism of Action
Understanding how AOD-9604 works requires a brief primer on growth hormone biology and fat metabolism.
Growth Hormone and Lipolysis
Growth hormone (GH) is a 191-amino acid protein secreted by the pituitary gland. Among its many functions, GH stimulates lipolysis — the breakdown of stored fat (triglycerides) in adipose tissue (fat cells) into free fatty acids, which can then be used as energy. It also inhibits lipogenesis, the process by which the body creates and stores new fat.
Most of GH's growth-promoting effects are mediated indirectly through Insulin-Like Growth Factor 1 (IGF-1), which is produced in the liver in response to GH signaling. The IGF-1 pathway drives protein synthesis, cellular proliferation, and tissue growth.
The key research question that drove AOD-9604 development was: Is the lipolytic activity of GH separable from its IGF-1-mediated growth effects?
How AOD-9604 Is Proposed to Act
Published data indicates that AOD-9604 appears to interact with fat cells through a pathway that does not involve the classical GH receptor in the same way full-length hGH does — or at minimum, does not trigger the downstream IGF-1 cascade to the same degree.
At the cellular level, research suggests the peptide may:
- Stimulate lipolysis in adipocytes (fat cells) by activating beta-3 adrenergic receptors — receptors on fat cells that, when activated, trigger the breakdown of stored triglycerides
- Inhibit lipogenesis by interfering with the conversion of dietary carbohydrates into fat stores
- Modulate fat oxidation — the rate at which fatty acids are burned for energy
Studies have demonstrated that AOD-9604 does not** significantly affect blood glucose levels or insulin sensitivity in research models, a notable distinction from full-length hGH, which can induce insulin resistance at higher concentrations.
This pharmacological profile — lipolytic activity without significant glucometabolic disruption — is one of the primary reasons AOD-9604 has attracted sustained research interest.
It's also worth noting that AOD-9604 has demonstrated a favorable safety profile in preclinical models, which contributed to it receiving GRAS (Generally Recognized As Safe) status from the U.S. Food and Drug Administration — a designation relevant to its use as a food additive in certain contexts, though this should not be interpreted as approval for any therapeutic application.
Published Research on AOD-9604
The research literature on AOD-9604 is more substantial than many peptides in this space, partly because it was developed by a pharmaceutical company (Monash University spin-out, Metabolic Pharmaceuticals) and advanced through early clinical research phases. Here's a summary of key published findings.
Preclinical Research: Animal Models
Heffernan et al. (1997) published foundational work establishing that the C-terminal fragment of hGH retained lipolytic activity. This early research demonstrated that the 177–191 region of hGH could stimulate fat breakdown in isolated adipocytes and in obese rodent models (ob/ob mice), reducing body weight without the growth effects seen with full-length GH. This work laid the conceptual groundwork for AOD-9604's development.
A series of studies from Metabolic Pharmaceuticals — including work published by Ng et al. — used diet-induced obese (DIO) mice to examine the fragment's effects on body composition. These studies found that rodents administered the fragment showed reduced fat mass and changes in fat distribution compared to controls, with no significant effect on lean body mass, blood glucose, or IGF-1 levels.
Research suggests that in rodent models, the peptide fragment preferentially mobilizes fat from visceral adipose tissue (fat stored around internal organs) — the metabolically active fat depot most closely associated with cardiometabolic risk factors in research literature.
Human Research: Phase IIa and IIb Clinical Studies
AOD-9604 is one of the few peptide fragments that progressed into human clinical research phases — a fact that gives the available data more weight than many analogous compounds.
Stier et al. (2004) conducted a Phase IIa clinical study examining AOD-9604 in overweight adult subjects. Published in Obesity Research, the study found a statistically significant reduction in body weight in subjects receiving certain research doses compared to placebo over a 12-week period. Importantly, no significant adverse effects on blood glucose, insulin, lipids, or IGF-1 were observed.
(PubMed ID: 15090625)
A subsequent Phase IIb multicenter clinical trial evaluated AOD-9604 across a larger subject group over a longer research period. While the results demonstrated trends toward fat reduction — particularly in subjects with higher baseline body mass — the primary endpoints did not reach the statistical thresholds required for regulatory advancement. This outcome is important context: it illustrates both the genuine biological signal researchers were pursuing and the complexity of translating peptide pharmacology into clinical efficacy at scale.
Human research involving AOD-9604 has consistently demonstrated a favorable safety profile** across multiple studies, with published data indicating no significant disruption to the hypothalamic-pituitary axis (the hormonal feedback system governing GH and related hormones).
Cartilage and Tissue Research — An Unexpected Research Direction
More recent research has examined AOD-9604 in a context somewhat removed from its anti-obesity origins: cartilage repair and joint tissue biology.
Guo et al. (2015) published research in PLoS ONE (PubMed ID: 25875077) examining the effects of AOD-9604 on chondrocytes (the cells that make up cartilage) and in models of osteoarthritis (degenerative joint disease). The study found that AOD-9604 promoted the production of extracellular matrix components — the structural scaffolding of cartilage — and demonstrated potential for supporting cartilage integrity in research models.
This line of research has expanded interest in AOD-9604 beyond metabolic biology, suggesting the peptide may have broader tissue-level effects worth investigating.
Research suggests that AOD-9604's effects on cartilage tissue may involve TGF-β signaling (Transforming Growth Factor Beta — a protein pathway involved in cell growth, tissue repair, and immune regulation), though the precise mechanisms remain an active area of study.
Practical Research Information
Physical Properties and Solubility
AOD-9604 is typically supplied as a lyophilized (freeze-dried) white powder. For reconstitution in research settings, it is generally soluble in:
- Sterile water
- Bacteriostatic water (water preserved with a small amount of benzyl alcohol, commonly used for peptide reconstitution)
- Dilute acetic acid (0.1–1%) — useful for peptides that don't fully dissolve in plain water
The peptide has a molecular weight of approximately 1815.12 Da (Daltons) — relatively small for a peptide fragment, which contributes to its stability compared to full-length proteins.
Storage and Stability
Proper storage is critical for maintaining peptide integrity. Published guidance for AOD-9604 research preparations generally indicates:
| Storage Condition | Recommended Duration |
|---|---|
| Lyophilized, −20°C (frozen) | Up to 24 months |
| Lyophilized, 2–8°C (refrigerated) | Up to 6 months |
| Reconstituted, 2–8°C | Up to 30 days |
| Reconstituted, −20°C | Up to 3 months (avoid repeated freeze-thaw) |
Practical note for researchers: Once reconstituted, peptide solutions should be protected from light and temperature fluctuations. Repeated freeze-thaw cycles degrade peptide structure and should be avoided by aliquoting (dividing into small single-use portions) at the time of reconstitution.
Research Dose Context
Published clinical research has used a range of quantities across studies. The Phase IIa human research by Stier et al. examined daily research doses ranging from 1 mg to 30 mg, with a 1 mg daily quantity appearing in the published literature as showing metabolically relevant effects without adverse signals. This information is provided purely as research context from published studies and does not constitute dosing guidance for human use.
Research Considerations
Comparing AOD-9604 and HGH Fragment 176-191
Researchers frequently encounter both AOD-9604 and HGH Fragment 176-191 and wonder how they differ. Here's a concise comparison:
| Parameter | AOD-9604 | HGH Fragment 176-191 |
|---|---|---|
| Sequence | Tyr-hGH(177–191) | hGH(176–191) |
| N-terminal modification | Yes (tyrosine added) | No |
| Molecular weight | ~1815 Da | ~1817 Da |
| Stability | Slightly enhanced | Standard |
| Research data volume | Higher (clinical data exists) | Preclinical-focused |
| Mechanism (proposed) | Lipolysis, lipogenesis inhibition | Lipolysis, lipogenesis inhibition |
For most research purposes, the compounds are studied with broadly similar hypotheses — the structural difference is subtle, but AOD-9604's modification was specifically designed with bioavailability and stability in mind.
What the Research Does and Doesn't Tell Us
It's worth being precise about the state of the evidence:
What published data supports:
- Lipolytic activity in adipocyte cell models
- Reduced fat mass in rodent obesity models
- A statistically significant weight reduction signal in Phase IIa human research
- A consistent favorable safety profile across preclinical and early clinical research
- Potential effects on cartilage tissue biology
What the research does not yet establish:
- Long-term effects beyond 12-week research windows
- Precise receptor binding mechanisms in human tissue
- Optimal research parameters across different biological contexts
- Efficacy in Phase III clinical settings (trials did not proceed to this stage)
Researchers approaching AOD-9604 work should situate it in the context of early-phase human data — more robust than many peptides in the research market, but not yet at the level of a fully characterized pharmaceutical compound.
Regulatory and Sourcing Considerations
AOD-9604 holds GRAS status in the United States for specific food additive contexts, which is a meaningful data point about its safety characterization — but researchers should note that GRAS status is distinct from drug approval and doesn't govern its use as a research compound.
For researchers sourcing AOD-9604, purity documentation is essential. Published research has consistently used >95% purity preparations. Reputable suppliers like MiPeptidos provide Certificate of Analysis (CoA) documentation — third-party analytical testing that confirms peptide identity, purity, and absence of contaminants. Researchers should request and review CoA documentation as a standard step before initiating any research protocol.
High-Performance Liquid Chromatography (HPLC) — a technique that separates and quantifies the components in a sample — and Mass Spectrometry (MS) — which confirms molecular identity by measuring molecular weight — are the standard analytical methods used in quality verification for research-grade peptides.
Peptide Handling Best Practices
A few notes that experienced peptide researchers consider standard practice:
- Minimize exposure to air during reconstitution — oxidation can degrade sensitive residues
- Use low-protein-binding syringes and vials where possible to reduce adsorption (the peptide sticking to container surfaces)
- Document your reconstitution date clearly on all vials
- Maintain cold chain from supplier receipt through storage
Summary
AOD-9604 occupies a genuinely interesting position in peptide research: it's a structurally well-defined fragment with a clear mechanistic hypothesis, a meaningful body of preclinical data, and the relatively rare distinction of having advanced into human clinical research phases. Published data indicates it demonstrates lipolytic activity without significant disruption to the IGF-1 axis or glucometabolic parameters — characteristics that have made it a sustained focus of metabolic research.
The cartilage research is an emerging area that opens additional research directions. And as with all compounds in this space, the honest summary is that there is more to learn — which is precisely why rigorous, well-documented research continues.
Researchers interested in related compounds may also want to review the available literature on HGH Fragment 176-191 as a complementary reference point.
Disclaimer
For research purposes only. Not for human consumption.
AOD-9604 is intended exclusively for use in licensed research settings by qualified professionals. The information presented in this article is compiled from published scientific literature for educational purposes and does not constitute medical advice, clinical guidance, or endorsement of any therapeutic application. This compound has not been approved by the FDA or any equivalent regulatory body for human therapeutic use. All research involving peptide compounds should be conducted in accordance with applicable institutional, local, and national regulations. MiPeptidos makes no claims regarding the safety or efficacy of this compound for any application beyond documented research contexts.